Discover
Discover
Start your journey here
Discover the world’s international exchange
Our regions
Our regions
United Kingdom
Europe
Middle East
Israel
Africa
Americas
Asia Pacific
China
London Stock Exchange Stock Connect
News and insights
News and insights
Latest
Welcome stories
Insights and reports
Press releases
Events
Events
Welcome stories
London Stock Exchange Market Ceremonies
LSEG
LSEG
LSEG products and services
Our history
News and Prices
News and Prices
Start your journey here
News and Prices
FTSE indices
FTSE indices
FTSE 100
FTSE 250
FTSE 350
FTSE All-Share
Prices and Markets
Prices and Markets
Search by Market
Bond search
Retail bonds search
ETFs search
Advanced bond search
News
News
Today's news
Regulatory news (RNS)
Reports
Reports
Issuers and instruments
Primary markets
Secondary markets
Group statistics
New issues
New issues
Upcoming issues
Recent issues
Raise Finance
Raise Finance
Start your journey here
Raise Finance
Equity
Equity
AIM
Main Market
Private Markets
Compare markets for listing equity
Direct Listings
SPACs
Calculating fees
How to list equity
Debt
Debt
Main Market
International Securities Market
Compare our debt markets
Our products
Calculating fees
How to list debt
ETPs
ETPs
ETFs
ETCs and ETNs
Calculating fees
How to list ETPs
Investment funds
Investment funds
Compare markets for listing funds
Specialist Fund Segment
Single Asset Listings
REITs
How to list funds
Sustainable Finance
Sustainable Finance
The Voluntary Carbon Market Designation
Low-Carbon Transition & Climate Reporting
Green Economy Mark
Sustainability Reporting Guide
Sustainable Bond Market
Equities Trading
Equities Trading
Start your journey here
Equities Trading
Equities Trading
London Stock Exchange
Turquoise
Turquoise Europe
TRADEcho
Membership
Membership
Member firm directory
Member firm information sheets
Member services
Asset Classes
Asset Classes
Shares
Global Depository Receipts
ETPs
Debt
Retail Brokers & Intermediaries
Retail Brokers & Intermediaries
Retail Broker Order Book Scheme
Retail Investor Market Data End User Fee Waiver
Direct Market Access
Turquoise Retail Max™
Market Data
Market Data
Market data licensing
Real-time data
Historical data products
Pricing and policies
Market Connectivity
Market Connectivity
Exchange Hosting
Customer Managed Connectivity
Third Party Connectivity
Customer Certification and Testing Services
Personal Investing
Personal Investing
Start your journey here
Personal Investing Hub
Tools
Tools
My account
Prices and markets search
Email alerts
Virtual Portfolio and Watchlist
Historical Price Service
Find a Broker
Direct Market Access
Broker directory
Broker directory
Execution only
Advisory
Discretionary
All articles
All articles
Why investing matters
What should you consider before investing
What are stocks & shares
Resources
Resources
Start your journey here
Resources
Raise finance
Raise finance
Main Market
AIM
Debt
Exchange Traded Products
Funds
Equities Trading
Equities Trading
Rules and regulations
Technical library
Shares
Debt
Exchange Traded Products
Membership
London Stock Exchange notices
London Stock Exchange notices
2025
2024
2023
2022
2021
2020
2019
2018
2017
Service Announcements
Service Announcements
2025
2024
2023
2022
2021
2020
2019
2018
2017
FAQs
FAQs
Website FAQs
Main Market
AIM
Debt
Exchange Traded Products
Funds
Home
>
News and Prices
>
Prices and Markets
>
HVIVO Plc
HVIVO Plc
Share
Company page
Our story
Webcasts
Trade recap
Fundamentals
Analysis
Address
40 Bank Street, Floor 24, London, E14 5NR, United Kingdom
Map
Website
hvivo.com
Industry classification
What's this?
FTSE industry
Health Care
FTSE supersector
Health Care
FTSE sector
Health Care Providers
FTSE subsector
Health Care Services
FCA listing Category
-
Issuer Market Cap £m
68.70
Admission date
14 December 2012
Country of Incorporation
GB
Media
from HVIVO Plc
hVIVO Clinical Site Services in Whitechapel
hVIVO Year in Review: Milestones, Growth and 2025 Ambitions
hVIVO secures fresh contract to round out "wonderful" year
Acquisition of Cryostore for up to £3.2 million
Interim Results Vox Markets
hVIVO Full Year Results year end 31 Dec 2023 Interview
hVIVO expands hMPV research with £2M deal
17 Feb 2025
New RSV Human Challenge Trial & Company Growth
hVIVO achieves record first-half revenue as it expands with new Canary Whart headquarters
Trading Update Jan 2025 & CRS Acquisition
Chief Scientific Officer Andrew Catchpole at WVCEU
World Vaccine Congress Europe
Canary Wharf Facilities Walk-Through
Company Presentation January 2024
Trading Update Jan 2024 - Investor Meet Company
VP of Clinical Operations on hLAB - Industry Leader in Virology & Immunology
hVIVO Acquires Cryostore
27 February 2025
hVIVO Timeline
£11.5 million contract with an existing top-tier global pharmaceutical client
10 December 2024
hVIVO secures £2.5mln contract for Omicron characterisation study
hVIVO secures fresh contract to round out "wonderful" year
hMPV Challenge Model Update
13 January 2025
FY24 Results Presentation
10 April 2025
hMPV Challenge Study Update - Pilot Study
13 January 2025
Chief Scientific Officer on Human Challenge Trials and Canary Wharf
Walk Through Tour Plumbers Row
£2 million contract for final stage of hMPV characterisation study
17 Feb 2025
hVIVO Trading Update H1 2024
hVIVO has secured a £2.7 million contract for hLAB
21 January 2025
Scientific Poster - Incidental Myocarditis in Healthy Adults Following RSV Inoculation
hVIVO CEO on record FY24 revenue & EBITDA as expansion strategy pays off
10 April 2025
hVIVO secures RSV trial deal with Inhalon Pharma in the US
3 February 2025
Interims Results H1 2023 - Vox Markets Interview
hVIVO achieves record revenue and initiates dividend policy
hVIVO Canary Wharf New Facilities
hVIVO CEO discusses Record Revenue H1 and Strategic Expansion
Interims 6 month ended 30 June 2024
hVIVO Year in Review 2024
Record 2024 revenue and strategic CRS acquisition
hVIVO signs £11.5M RSV trial contract; expands services at new facility
10 December 2024
hVIVO secures record £2.7M laboratory services contract
21 January 2025
Canary Wharf Facility in 3 Words
HVO FY24 Results - VOX Markets Interview
10 April 2025
£2.5 Million Contract for Omicron Characterisation Study
Interview with Vox Markets and CEO Yamin 'Mo' Khan
hVIVO Interim Results H1 2024
Investor Meet Company Presentation on 10 September 2024.
hVIVO Move to Canary Wharf
hVIVO Clinical Site Services in Whitechapel
hVIVO Year in Review: Milestones, Growth and 2025 Ambitions
hVIVO secures fresh contract to round out "wonderful" year
Acquisition of Cryostore for up to £3.2 million
Next
Twitter feed
From HVIVO Plc